Clinical Trials Logo

Obstructive Pulmonary Disease clinical trials

View clinical trials related to Obstructive Pulmonary Disease.

Filter by:

NCT ID: NCT06149494 Recruiting - Copd Clinical Trials

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.

NCT ID: NCT05654597 Recruiting - Lung Diseases Clinical Trials

French Validation of the CAPTURE Case Finding Tool for Obstructive Respiratory Disease

Start date: April 1, 2023
Phase:
Study type: Observational

The objective of this multicentre prospective study is to validate CAPTURE as a French case finding tool for undiagnosed patients suffering from obstructive pulmonary disease.

NCT ID: NCT05250128 Not yet recruiting - Clinical trials for Obstructive Pulmonary Disease

The Significance of Circulating Microvesicles in Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

MICROBOPH
Start date: September 2022
Phase:
Study type: Observational

Mild to moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased survival. A small proportion of COPD patients may present with severe pulmonary hypertension, defined by a mean pulmonary artery pressure more than 35 mmHg (or more than 20 mmHg with a low cardiac index < 2 l/min/m2) with pulmonary vascular resistance more than 3 Wood units, measured by right heart catheterization (RHC). In these patients, pulmonary microvessels remodeling is the main cause of increase in pulmonary arterial pressure and is thought to result from the combined effects of hypoxia, inflammation, and loss of capillaries but the mechanisms are complex. For these patients, no drugs have been approved for treatment and lung transplantation must be considered for the more severe patients who are eligible. A better characterization of these patients is needed. We hypothesize that microvesicles generation and endothelial damage could be related to the severity of pulmonary hypertension due to COPD, assessed by pulmonary hemodynamic parameters. Circulating biomarkers of vascular damage and cell activation will be measured in blood samples from 80 COPD patients who have hemodynamic assessment by RHC. To go further, the origin of the particles will be characterized.

NCT ID: NCT05028985 Recruiting - Clinical trials for Obstructive Pulmonary Disease

Early COPD for China Pulmonary Health Study Stage II

EC-CPHS
Start date: January 1, 2021
Phase:
Study type: Observational

Discovery of the pathogenesis and targets in the progression of early chronic obstructive pulmonary disease

NCT ID: NCT04820556 Completed - Asthma Clinical Trials

Gut Microbiota in Chronic Noncommunicable Diseases

Start date: April 12, 2021
Phase:
Study type: Observational

It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control group with no signs of these conditions. The study has a prospective part planned for 2021 and a retrospective part which includes the patients enrolled between 2018-2020. The aim of the study is to investigate gut microbiota composition, its metabolites, levels of inflammatory and other markers of the disease in prospective groups (arterial hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma, non-alcoholic fatty liver disease and control patients) as well as in retrospective groups (chronic heart failure with preserved and reduced ejection fraction, obstructive atherosclerosis of any vascular bed, arterial hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma, non-alcoholic fatty liver disease, and control patients). Also we are planning to investigate the association between gut microbiota composition and its metabolites, levels of inflammatory and other markers of the disease in retrospective and prospective groups.

NCT ID: NCT04748900 Completed - Clinical trials for Obstructive Pulmonary Disease

Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report

Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

A spirometry study is performed in a patient diagnosed with allergic bronchopulmonary aspergillosis. An initial measurement is carried out and the patient is then put on a four-week physiotherapy treatment plan. Four spirometry measurements were taken to assess different variables and an improvement in all the spirometry values was established.

NCT ID: NCT04668599 Active, not recruiting - Heart Failure Clinical Trials

Cardio-pulmonary Rehabilitation and Sleep Quality

Start date: May 11, 2020
Phase:
Study type: Observational

In this prospective cohort study the investigators aim to evaluate the effect of pulmonary rehabilitation on sleep quality. Disturbed sleep is associated with, frequent exacerbations, increase in the severity of disease and increased mortality in chronic obstructive pulmonary disease (COPD). Sleep quality is a good predictor of quality of life in patients with stable COPD. However, there has been little investigation into non-pharmacological methods to improve sleep quality in patients with COPD and heart failure. It is also uncertain, how long the beneficial effects of cardio-pulmonary rehabilitation on sleep quality, if any, usually last. Due to lack of robust data, the investigators sought to find the effect of cardio-pulmonary rehabilitation on sleep quality.

NCT ID: NCT04136951 Completed - Clinical trials for Diabetes Mellitus, Type 2

Improving Patient Prioritization During Hospital-homecare Transition

PREVENT
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This research work is focused on building and evaluating one of the first evidence-based clinical decision support tools for homecare in the United States. The results of this study have the potential to standardize and individualize nursing decision making using cutting-edge technology and to improve patient outcomes in the homecare setting.

NCT ID: NCT04050943 Recruiting - Clinical trials for Obstructive Pulmonary Disease

A Cohort of Patients With Chronic Pulmonary Disease

Start date: August 22, 2019
Phase:
Study type: Observational [Patient Registry]

This is a longitudinal study of following chronic pulmonary disease patients to observe and predict the clinical outcomes of these patients.

NCT ID: NCT04048408 Completed - Clinical trials for Cognitive Impairment

Comparison of Respiratory Muscle, Pain, Functional Performance and Cognitive Status in Obstructive Lung Diseases

Start date: January 1, 2019
Phase:
Study type: Observational

In the literature, there are a limited number of studies evaluating postural awareness, cognitive status, respiratory muscle strength and endurance, functional capacity, and pain in people with obstructive pulmonary disease, and comparing these parameters with each other and with healthy subjects, and most of the studies are on chronic obstructive pulmonary disease patients. There we will evaluate these parameters in different obstructive lung diseases and compare the findings of healthy individuals.